GlassScriptPhysician profile
Danielle Lefebvre
NPI 1114523727
$1,212.94
in general payments reported to CMS, 2019-2025
16 companies · $482 in 2025
The $482 reported for 2025 was more than what 85% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $50.63 · 2023: $255 · 2024: $426 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,087 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,087.32 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $255.40 | 2023-2025 | Veozah |
| Abbvie INC. | $200.36 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $149.15 | 2024-2025 | |
| Biogen, INC. | $119.80 | 2024-2025 | Zurzuvae |
| Shield Therapeutics INC | $80.58 | 2024-2025 | |
| Pfizer INC. | $66.02 | 2025 | |
| Organon LLC | $57.49 | 2024 | |
| Merck Sharp & Dohme LLC | $56.85 | 2023-2024 | Gardasil 9, Gardasil |
| Mayne Pharma Commercial LLC | $42.71 | 2025 | |
| Novo Nordisk INC | $41.61 | 2023-2025 | Wegovy |
| Millicent US INC | $33.34 | 2025 | Intrarosa, Femlyv |
| Sumitomo Pharma America, INC. | $32.59 | 2024-2025 | Myfembree |
| Agile Therapeutics, INC. | $28.43 | 2023-2024 | Twirla |
| Dexcom, INC. | $18.28 | 2025 | Dexcom G6 Transmitter |
| Coopersurgical, INC. | $17.43 | 2024 | Paragard T 380a |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $12.90 | 2023 | Olympus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Lefebvre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.